The goal of this Randomized controlled trial is to evaluate in household ambulatory, elderly patients sustaining femoral neck fracture who are subjected to be treat with cementless bipolar hemiarthroplasty. The main questions it aims to answer are: * The efficacy in reducing blood transfusion for topical tranexamic acid administration * The safety of tranexemic acid, topically used As having undergone bipolar hemiarthroplasty surgery, participants will either receive retrograde intraarticular tranexamic acid injection via drain tube, or topical soaking administration. Researchers will compare, with standard procedure (procedure), whether topically administered tranexamic acid would reduce rate of blood transfusion.
Perioperative blood loss and transfusion are common in elderly patients undergoing bipolar hemiarthroplasty for femoral neck fractures, and are associated with anemia-related morbidity and transfusion-related risk. Although tranexamic acid (TXA) reduces blood loss and transfusion in elective arthroplasty, topical administration has been proposed to preserve local hemostatic efficacy while limiting systemic exposure in this comorbid population, but the optimal topical route in hip fracture surgery remains uncertain. This study compared the efficacy and safety of topical soaking (TS) and intra-articular (IA) TXA with placebo in patients undergoing bipolar hemiarthroplasty.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
75
Tranexamic acid will be injected via drain tube after wound closure
Tranexamic acid will be topically administered by soaking method
Standard wound management
Faculty of Medicine, King Chulalongkorn Memorial Hospital
Bangkok, Bangkok, Thailand
RECRUITINGFaculty of Medicine
Bangkok, Bangkok, Thailand
NOT_YET_RECRUITINGRate of blood transfusion
Proportion of patients received blood transfusion divided by total number of patient in a group
Time frame: 2 years, or until complete enrollment
Volume of blood transfusion
total volume of blood transfusion per each patient
Time frame: 2 years, or until complete enrollment
Calculated blood loss
Calculating using Nadler and Goss formula
Time frame: 2 years, or until complete enrollment
Any adverse events
Adverse events include wound complication, deep vein thrombosis, pulmonary embolism, and other complication
Time frame: 2 years, or until complete enrollment
In-hospital mortality
In-hospital mortality
Time frame: During admission period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.